Antimicrobial Susceptibility Testing Market (2024-2031)
The Antimicrobial Susceptibility Testing Market was valued at $4.29 billion in 2023. This market is expected to reach $7.21 billion by 2031, from an estimated $4.58 billion in 2024, at a CAGR of 6.7% during the forecast period 2024-2031. Antimicrobial Susceptibility Testing Market Size & Forecast The
- Published
- May 2024
- Pages
- 182
- Format
- PDF + Excel
- Report ID
- MRHC - 104363
- Base year
- 2023
- 2023 · BASELINE
- $4.29B
- 2031
- $7.21B
- CAGR 2024–2031
- 6.7%
2023 baseline · 2024–2031 forecast at 6.7% CAGR · hover a bar for the value
Key highlights
By Product: In 2024, the Manual Antimicrobial Susceptibility Testing Products Segment to Dominate the Antimicrobial Susceptibility Testing Market
By Method: In 2024, the Disk Diffusion Segment to Dominate the Antimicrobial Susceptibility Testing Market
By Test Type: In 2024, the Antibacterial Tests Segment to Dominate the Antimicrobial Susceptibility Testing Market
By Application: In 2024, the Clinical Diagnostics Segment to Dominate the Antimicrobial Susceptibility Testing Market
By End User: The Diagnostic Laboratories and Hospitals Segment to Dominate the Antimicrobial Susceptibility Testing Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 182 |
| Format | |
| Forecast Period | 2024–2031 |
| Base Year | 2023 |
| CAGR (Value) | 6.7% |
| Market Size (Value) | USD 7.21 Billion by 2031 |
| Segments Covered | By Product · Manual Antimicrobial Susceptibility Testing Products · Susceptibility Disks · Susceptibility Plates · Minimum Inhibitory Concentration (MIC) Strips · Consumables · Automated Antimicrobial Susceptibility Testing Products · By Method · Disk Diffusion · Automated AST · Dilution · Other Methods · (Note: Other Methods Etest, genotypic methods, and MALDI-TOF MS) · By Test Type · Antibacterial Tests · Anti-parasitic Tests · Antifungal Tests · Other Test Types · By Application · Clinical Diagnostics · Drug Discovery and Development · Other Applications · (Other Applications include epidemiology, veterinary diagnostic, and environmental monitoring) · By End User · Diagnostic Laboratories and Hospitals · Pharmaceutical and Biotechnology Companies · Research and Academic Institutes |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Denmark, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), HiMedia Laboratories Pvt. Ltd. (India), MERLIN Diagnostika GmbH (Germany), Accelerate Diagnostics, Inc. (U.S.), Alifax S.r.l. (Italy), Creative Diagnostics (U.S.), Synbiosis (U.K.), and Zhuhai DL Biotech Co., Ltd (China) |
Report overview
Segments covered: product, susceptibility disk, susceptibility plate, consumable, method, disk diffusion, automated ast, dilution, other method, test type, antibacterial test, anti-parasitic test, antifungal test, other test type, application, clinical diagnostic, drug discovery, development, other application, end user, diagnostic laboratory, hospital, pharmaceutical, biotechnology company, research, academic institute. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is attributed to the high prevalence of infectious diseases, government initiatives and funding toward antimicrobial susceptibility testing programs, technological advancements in the development of new AST methods, and the emergence of multidrug resistance in microorganisms. Moreover, emerging markets and active R&D to develop rapid antimicrobial susceptibility testing are expected to offer growth opportunities for the players operating in this market.
Report infographic
Market dynamics
5 factors across 3 forcesGovernment Initiatives to Tackle Antimicrobial Susceptibility Testing
Governments worldwide are focused on developing policies and strategies to combat antimicrobial resistance and drive research for the development of new antimicrobials. Various initiatives are being undertaken to create awareness regarding antimicrobial resistance testing and curb antimicrobial abuse, aiding in educating decision-makers, regulatory agencies, and other end users regarding the prevention of antimicrobial resistance.
For instance, in October 2020, the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), 2020–2025, was introduced to improve the health and well-being of all Americans by changing the course of antibiotic resistance. This plan prioritizes infection prevention and control to slow the spread of resistant infections and optimize antibiotic use.
Government initiatives for combating multidrug resistance are expected to boost the need for antimicrobial susceptibility testing products, thereby driving the growth of the global antimicrobial susceptibility testing market.
High Risk of Bloodstream Infections Globally
Invasion of the bloodstream by microorganisms poses severe health challenges. Bloodstream infections can result in serious consequences like disseminated intravascular coagulation, shock, multiple organ failure, or even death. Common bloodstream infections include sepsis, dengue fever, acquired immunodeficiency syndrome (AIDS), Hepatitis A, Hepatitis B, and Hepatitis C. Common pathogens include Neisseria meningitidis, Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Salmonella typhi, E. coli, Klebsiella spp, and human immunodeficiency virus (HIV). According to an article published by Vanderbilt University Medical Center in March 2021, mortality rates due to bloodstream infections range between 12% and 32% in North American and European countries.
Sepsis is among the most common types of bloodstream infections and may lead to organ dysfunction. According to WHO statistics updated in August 2020, there were 48.9 million cases of sepsis, with around 11 million sepsis-related deaths globally. Blood culture is the gold standard for diagnosing septicemia. Antibiotics are critical tools for treating life-threatening infections such as sepsis, so the demand for antibiotic sensitivity testing is high in determining the use of the right antimicrobials.
Table of contents
13 chapters · 105 sections · 182 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Product | Manual Antimicrobial Susceptibility Testing Products | — |
| By Method | Disk Diffusion | Automated antimicrobial susceptibility testing |
| By Test Type | Antibacterial Tests | — |
| By Application | Clinical Diagnostics | — |
| By End User | Diagnostic Laboratories and Hospitals | — |
By Product
- The manual antimicrobial susceptibility testing segment is expected to account for the largest share of above 52.8% of the antimicrobial susceptibility testing market.
- Manual antimicrobial susceptibility testing includes susceptibility disks, susceptibility plates, and minimum inhibitory concentration strips.
- The growing use of antimicrobial susceptibility testing to devise targeted antimicrobial therapy for people and the growing emergence of antibiotic resistance cases are driving the demand for conventional antimicrobial susceptibility testing techniques.
- High penetration of disk diffusion technique and developments in susceptibility plates are the factors driving manual antimicrobial susceptibility testing and related products market.
- Furthermore, manual products provide flexibility and allow possible cost savings by using methods like disk diffusion and gradient diffusion methods.
By Method
- The Disk Diffusion Segment to Dominate the Antimicrobial Susceptibility Testing Market
- The disk diffusion segment is expected to account for the largest share of above 37.6% of the antimicrobial susceptibility testing market.
- The large share of the segment is attributed to factors such as the test simplicity that does not require any special equipment, the provision of categorical results easily interpreted by all clinicians, and flexibility in the selection of disks for testing.
- The low cost of performing AST testing with the disk diffusion methods and developments in the method with automated technology are primarily boosting the segment market growth.
- However, the automated antimicrobial susceptibility testing segment is expected to grow at the fastest CAGR of above 8.1% during the forecast period of 2024–2031.
- The use of instrumentation can standardize the reading of endpoints and often produce susceptibility test results in a shorter period than manual readings because sensitive optical detection systems detect subtle changes in bacterial growth.
- The key factors driving the adoption of automated AST are growing acceptance for automated systems due to relatively accurate and conservative assessment of MICs for most antimicrobials and faster turnaround time of automated AST compared to manual methods.
By Test Type
- The antibacterial tests segment is expected to account for the largest share of the antimicrobial susceptibility testing market.
- Antibacterial susceptibility tests are procedures that are performed by laboratory professionals to identify an antimicrobial regimen for patients as per their infection type.
- The large share of the segment is attributed to factors such as higher use of antibacterial tests in clinical diagnosis, growing incidence of bacterial infections, the emergence of antibiotic-resistant bacteria, cost-effectiveness, simplicity, and fast interpretation, ease of use, and availability.
By Application
- The clinical diagnostics segment is expected to account for the largest share of the antimicrobial susceptibility testing market.
- Clinical microbiology detection plays a significant role in the diagnosis of infectious diseases, medication guidance, nosocomial infection control, and antimicrobial management.
- It helps in the evaluation of treatment services provided by healthcare centers.
- The large share of the segment is attributed to factors such as the rising burden of antibiotic resistance, increasing incidence of HAIs, the growing procedural volume of clinical diagnostic tests, rising emphasis on effective and early disease diagnosis across major markets, and growing awareness among physicians about antimicrobial susceptibility testing methods.
By End User
- The diagnostic laboratories and hospitals segment is expected to account for the largest share of the market.
- The increasing prevalence of infectious diseases and the emergence of microbial resistance against existing antimicrobial treatment options are compelling clinicians to perform AST at hospitals and diagnostic labs.
- The large share of the segment is attributed to the availability of well-equipped facilities and trained/skilled technicians, the rise in hospital-acquired infections, and initiatives taken by key players to offer AST products through diagnostic laboratories & hospitals.
Geographic analysis
North America
Largest shareIn 2024, North America is expected to account for the largest share of above 43.9% of the antimicrobial susceptibility testing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The largest share of the segment is primarily due to the presence of leading manufacturers, large R&D investments, support from government and regulatory authorities, rising antibiotic resistance, and increasing government initiatives to fight antibiotic resistance. According to the CDC, antimicrobial resistance is one of the biggest public health challenges in the U.S. The annual incidence of antibiotic resistance in the U.S. was 2.8 million, with over 35,000 associated deaths. Drug-resistant Candida species are commonly detected among in-patients. As per the same report, nearly 7% of bloodstream infections due to Candida species are resistant to antifungals. Common yeast infections caused by Candida species result in over 3.6 million U.S. healthcare visits annually, with a direct medical cost of USD 3 billion. By Geography: North America Region to Dominate the Antimicrobial Susceptibility Testing Market
Asia-Pacific
Fastest growthHowever, Asia-Pacific is slated to register the fastest CAGR of above 8.8% during the forecast period. The growing consumption of antibiotics, high prevalence of bloodstream infections, rising incidence of HIV/AIDS, and growing antimicrobial resistance drive the demand for antimicrobial susceptibility testing in the region. Further, the growing focus of government policies on combating antimicrobial resistance also supports the growth of this market.
Competitive landscape
As of 2023, Thermo Fisher Scientific, Inc. (U.S.), bioMérieux S.A (France), and Danaher Corporation (U.S.) collectively hold a share of 60%-65% in the global antimicrobial susceptibility testing market.
- February 2023
BioMérieux S.A. (France) launched MAESTRIA, which is microbiology middleware that manages specimens from the moment they are logged into the laboratory workflow.
- July 2021
Accelerate Diagnostics, Inc. (U.S.) announced the launch of its new IVD configuration of its Accelerate PhenoTest BC Kit in the U.S., which provides fast antimicrobial susceptibility testing (AST) results in approximately 7 hours.
- April 2021
Becton, Dickinson, and Company (U.S.) launched the BD MAX Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay that is used for the high diagnostic accuracy testing for tuberculosis and is recognized by the World Health Organization (WHO).
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA · Germany
- Bio-Rad Laboratories, Inc. (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Danaher Corporation (U.S.)
- HiMedia Laboratories Pvt. Ltd. · India
- MERLIN Diagnostika GmbH · Germany
- Accelerate Diagnostics, Inc. (U.S.)
- Alifax S.r.l · Italy
- Creative Diagnostics (U.S.)
- Synbiosis (U.K.)
- Zhuhai DL Biotech Co., Ltd · China
Frequently asked questions
This market study covers the market sizes and forecasts of antimicrobial susceptibility testing based on product, method, test type, application, end user, and geography. It also provides the value analysis of various segments and sub-segments of the global antimicrobial susceptibility testing market at country levels.
Cite this report
Meticulous Research. (2024). Antimicrobial Susceptibility Testing Market - Global Opportunity Analysis and Industry Forecast (2024-2031) (Report No. MRHC - 104363). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/antimicrobial-susceptibility-testing-market-5062